Send us a text with a question or thought on this episode ( We cannot replay from this link)
We trace how endometriosis interacts with mast cells, connective tissue, and hormones, explaining why symptoms feel systemic and why overlap with HEDS and MCAS appears so often. We also review new data on tirzepatide and inflammation, separating promise from hype while keeping care practical and multidisciplinary.
• Mast cell activation as a shared pathway across HEDS and endometriosis
• EMT signaling via CCL2 and CCR4 and its role in lesion persistence
• Estrogen’s influence on immune activity and symptom flares
• Systemic symptom map spanning gut, bladder, fatigue and brain fog
• Antihistamines and stabilizers as volume-down tools, not cures
• Evidence on tirzepatide lowering CRP and IL‑6 with caveats
• Why correlation is not causation and why it still matters
• Multidisciplinary care to align gynecology, immunology and rheumatology
Share this episode with someone who needs validation, comment your experience so others feel less alone, and keep advocating for yourself
Mast Cell–Mediated Epithelial–Mesenchymal Transition in Endometriosis
hypermobile Ehlers-Danlos Syndrome (hEDS) and mast cells
The Role of Mast Cells in Endometriosis
Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis
Website endobattery.com
